Evidence map›Paper›PMID 34125273›Full record

ArticleCurrent microbiology2021

Taxonomic and Metabolomics Profiling of Actinobacteria Strains from Himalayan Collection Sites in Pakistan.

Mohsin T Cheema, Larissa V Ponomareva, Tao Liu, S Randal Voss, Jon S Thorson, Khaled A Shaaban, Imran Sajid

Open access · greenAbstract read
In one paragraph

Article in Current microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Mohsin T CheemaInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Larissa V PonomarevaCenter for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, 40536, USA.ORCID http://orcid.org/0000-0003-2182-8774
Tao LiuCenter for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, 40536, USA.
S Randal VossDepartment of Neuroscience, University of Kentucky, Lexington, KY, 40536, USA.ORCID http://orcid.org/0000-0002-8332-3176
Jon S ThorsonCenter for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, 40536, USA.ORCID http://orcid.org/0000-0002-7148-0721
Khaled A ShaabanCenter for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, 40536, USA. khaled_shaaban@uky.edu.ORCID http://orcid.org/0000-0001-7638-4942
Imran SajidInstitute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan. imran.mmg@pu.edu.pk.ORCID http://orcid.org/0000-0002-4781-1455
University of Kentucky · USUniversity of the Punjab · PK

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI M. Ashfaqul Alam · 2020 to 2026
$18.7M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Developing Regeneration Resources for a Model AmphibianR24OD021479 · OD · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT, VOSS, STEPHEN RANDAL · 2016 to 2019
$2.3M
Platform technologies for understanding and exploiting methylationR01GM115261 · NIGMS · UNIVERSITY OF KENTUCKY · PI PHILLIPS, GEORGE NEAL, THORSON, JON SCOTT · 2016 to 2019
$2.2M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NIGMS NIH HHS P20 GM130456NIGMS NIH HHS R01 GM115261NIH HHS R24 OD021479NIH HHS R24 OD21479 (SRV, JST), R01 GM115261 (JST)
6 · The paper itself

Abstract

Actinobacteria have proven themselves as the major producers of bioactive compounds with wide applications. In this study, 35 actinobacteria strains were isolated from soil samples collected from the Himalayan mountains region in Pakistan. The isolated strains were identified by polyphasic taxonomy and were prioritized based on biological and chemical screening to identify the strains with ability to produce inimitable metabolites. The biological screening included antimicrobial activity against Staphylococcus aureus, Micrococcus luteus, Salmonella enterica, Escherichia coli, Mycobacterium aurum, and Bacillus subtilis and anticancer activity using human cancer cell lines PC3 and A549. For chemical screening, methanolic extracts were investigated using TLC, HPLC-UV/MS. The actinobacteria strain PU-MM93 was selected for scale-up fermentation based on its unique chemical profile and cytotoxicity (50-60% growth inhibition) against PC3 and A549 cell lines. The scale-up fermentation of PU-MM93, followed by purification and structure elucidation of compounds revealed this strain as a promising producer of the cytotoxic anthracycline aranciamycin and aglycone SM-173-B along with the potent neuroprotective carboxamide oxachelin C. Other interesting metabolites produced include taurocholic acid as first report herein from microbial origin, pactamycate and cyclo(L-Pro-L-Leu). The study suggested exploring more bioactive microorganisms from the untapped Himalayan region in Pakistan, which can produce commercially significant compounds.

Indexed as

ActinobacteriaAnti-Bacterial AgentsHumansMetabolomicsMicrobial Sensitivity TestsMycobacteriaceaePakistanAnti-Bacterial Agents

Identifiers

PMID34125273
PMCPMC10716794
OpenAlexW3172957532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.